24 patients diagnosed with neurological diagnosis and unresponsive to standard treatments were recruited and received four 2-week treatments. Patients were randomly assigned to receive sublingual sprays of either delta-9-tetrahydrocannabinol (THC) only, cannabidiol (CBD) only, 1:1 THC and CBD preparation, or placebo during each 2-week treatment session. Results demonstrated that compared to placebo, there was a significantly greater improvement of pain in the CBD group and the THC group, spasm in the THC group and the THC:CBD group, and spasticity in the THC group. There was no significant difference in improving bladder control and coordination between any of the 3 treatment groups compared to placebo.